Mar 31, 2023
De novo antibodies are here.
AI and synthetic biology are unlocking new opportunities to create de novo antibodies, which could potentially reduce the time it takes to get new drug candidates into the clinic by more than half, while also increasing their probability of success in the clinic.
Absci achieved a breakthrough in generative AI drug creation: We are the first to design and validate de novo therapeutic antibodies with zero-shot generative AI.
Creating antibodies in silico with generative AI represents a major industry breakthrough on the path to fully de novo antibody design and our vision to deliver breakthrough therapeutics at the click of a button, for everyone.
Read the bioRxiv preprint manuscript here
Please note that the preprint manuscript has not undergone peer review, the findings are provisional, and the conclusions may change.